Retina

Michael Singer, MD, speaks at the American Society of Retina Specialists meeting

Paolo Antonio Silva, MD, discussed his upcoming ASRS presentation on diabetic retinopathy lesions

Ahead of the ASRS meeting in Stockholm, Sweden, Danny Mammo, MD, discusses use of suprachoroidal triamcinolone acetonide in non-infectious uveitis

Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204 for the treatment of geographic atrophy

Theodore Leng, MD, MS, speaks about his ASRS presentation, focusing on the FARETINA-DME Study

Ahead of the ASRS meeting, Rishi P. Singh, MD, previews results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy

Carl C. Awh, MD, FASRS, gives an overview of the Phase 3 Pagoda trial year 2 results

Carl J. Danzig, MD, discusses efficacy, safety, and durability of faricimab in macular oedema due to retinal vein occlusion

This year, the ASRS meeting will feature an expert panel on sustainability — learn more from panelist Martin Zinkernagel, MD, PhD

Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal geographic atrophy

Four retina specialists share what they're most looking forward to at the 2024 ASRS meeting

Jennifer I. Lim, MD, FARVO, FASRS, discusses her ASRS presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy"

Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July

The company has secured $170 million (approximately €157 million) in Series B funding

Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular oedema

The drug is a biosimilar for aflibercept 2 mg (Eylea)

Apellis will seek re-examination from the CHMP following the opinion

A preview of presentations from 4D Molecular Therapeutics and Adverum Biotechnologies

The YOSEMITE/RHINE studies measured changes in the BCVA and CST from baseline to years 1 and 2

The prize, presented by EURETINA and supported by Oculis, will recognise outstanding contributions to retina research

The diagnostic and monitoring tools use artificial intelligence-based models

XLRP often leads to blindness by middle age with no treatment options currently available

The mapping method revealed prominent microscopic abnormalities consistent with DR